Recent News

• 08.07.2026 - Thailand’s competitive strength lies in its ability to consistently deliver high-quality clinical trials at scale
• 08.07.2026 - EU PPWR’s Two-Role Split Creates Costly Compliance Trap For Device Makers
• 08.06.2026 - ICON Announces Pricing of USD 2.15 Billion Notes
• 08.04.2026 - ICON Announces Private Offering of Notes
• 08.04.2026 - Operational discipline is a critical determinant of clinical utility for neurologic monoclonal antibodies
• 08.03.2026 - Why Europe, not America, may be Chinese sponsors’ smartest move
• 07.31.2026 - ICON Announces Results of Annual General Meeting
• 07.31.2026 - 2026 Annual General Meeting
• 07.31.2026 - Real-World Evidence in transition: CRO adaptation to the European Health Data Space framework
• 07.30.2026 - ICON partners with Anthropic in multi-year collaboration to deploy Claude's frontier AI across the clinical trial lifecycle

Recent Filings

• 08.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.06.2026 - EX-99.1 EX-99.1
• 08.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.31.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.31.2026 - EX-99.1 EX-99.1
• 07.30.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.29.2026 - EX-99.1 EX-99.1
• 07.22.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.22.2026 - EX-99.1 EX-99.1